Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has announced positive results from a new study that showed Ambien CR CIV tablets 12.5mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over eight weeks in patients with co-morbid insomnia and major depressive disorder who were administered a selective serotonin reuptake inhibitor for depression.
Subscribe to our email newsletter
Total sleep time was increased in the Ambien CR group throughout the study. At week eight, patients reporting sleeping an average of 101 minutes more than baseline compared to placebo-treated patients who reported sleeping an average 64 minutes more (P<0.0001). On average, Ambien CR-treated patients reported falling asleep sooner and exhibited improved sleep maintenance based upon fewer nighttime awakenings and decreased wake time after sleep onset compared to placebo-treated patients (P<0.0001). In addition, patients reported improvements in secondary measures related to daytime functioning, including morning energy, morning concentration and sleep impact on daily activities. Thomas Roth, director of the Sleep Disorders and Research Center at Henry Ford Hospital, said: "The results of this study demonstrate that Ambien CR can be considered a viable treatment option for the insomnia major depressive disorder patients experience and help them get the good night's sleep they need to improve their next-day functioning."